PT Millennium Pharmacon International Tbk

IDX:SDPC Stock Report

Market Cap: Rp168.2b

Millennium Pharmacon International Past Earnings Performance

Past criteria checks 1/6

Millennium Pharmacon International has been growing earnings at an average annual rate of 37.5%, while the Healthcare industry saw earnings growing at 3.7% annually. Revenues have been growing at an average rate of 7.2% per year. Millennium Pharmacon International's return on equity is 9.1%, and it has net margins of 0.7%.

Key information

37.5%

Earnings growth rate

37.7%

EPS growth rate

Healthcare Industry Growth14.1%
Revenue growth rate7.2%
Return on equity9.1%
Net Margin0.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Millennium Pharmacon International makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

IDX:SDPC Revenue, expenses and earnings (IDR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 243,847,83726,873215,5430
30 Jun 243,737,53725,293208,3800
31 Mar 243,583,66334,343200,0450
31 Dec 233,363,51833,088193,0070
30 Sep 233,247,23827,353191,3010
30 Jun 233,219,22333,687189,9230
31 Mar 233,140,96419,205191,1080
31 Dec 223,200,83324,464186,3110
30 Sep 223,110,80623,400181,6470
30 Jun 223,108,30320,180180,4060
31 Mar 223,118,51619,784176,7280
31 Dec 212,988,8499,571176,2140
30 Sep 212,964,4559,106170,5580
30 Jun 212,722,0382,264164,0610
31 Mar 212,542,135-3,080158,4260
31 Dec 202,643,6272,804159,8600
30 Sep 202,650,5982,481163,0800
30 Jun 202,732,4573,937161,2440
31 Mar 202,834,14710,608164,2380
31 Dec 192,726,7557,880159,7810
30 Sep 192,663,27111,359155,0480
30 Jun 192,606,48715,927152,2390
31 Mar 192,501,35420,139144,8160
31 Dec 182,376,18319,444140,9040
30 Sep 182,289,13619,468135,8890
30 Jun 182,217,57618,354134,7620
31 Mar 182,161,38513,437130,6540
31 Dec 172,110,82514,180125,8200
30 Sep 172,064,63713,749122,4480
30 Jun 171,981,7319,082119,8260
31 Mar 171,992,98712,039119,6240
31 Dec 161,970,11411,106118,2480
30 Sep 161,921,31011,723109,0010
30 Jun 161,871,47614,723106,2640
31 Mar 161,784,41212,970103,5750
31 Dec 151,707,61311,907101,2580
30 Sep 151,639,66413,34998,0220
30 Jun 151,575,67311,01895,1760
31 Mar 151,497,4807,04492,7430
31 Dec 141,437,6687,34089,1550
30 Sep 141,392,0325,86596,6440
30 Jun 141,369,2668,10394,6250
31 Mar 141,342,0309,98091,9590

Quality Earnings: SDPC has a large one-off gain of IDR12.7B impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: SDPC's current net profit margins (0.7%) are lower than last year (0.8%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: SDPC's earnings have grown significantly by 37.5% per year over the past 5 years.

Accelerating Growth: SDPC's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: SDPC had negative earnings growth (-1.8%) over the past year, making it difficult to compare to the Healthcare industry average (-1.8%).

Return on Equity

High ROE: SDPC's Return on Equity (9.1%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/30 04:00
End of Day Share Price 2025/01/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PT Millennium Pharmacon International Tbk is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution